<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease (BD) is a multisystem <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disorder</z:e> characterized by oral and <z:e sem="disease" ids="C0151281" disease_type="Disease or Syndrome" abbrv="">genital ulceration</z:e> and ocular involvement </plain></SENT>
<SENT sid="1" pm="."><plain>Recurrent oral and <z:hpo ids='HP_0003249'>genital ulcers</z:hpo> are the most common symptoms of BD and occur in more than 80% of patients </plain></SENT>
<SENT sid="2" pm="."><plain>The treatments of these disease manifestations include <z:chebi fb="0" ids="23359">colchicine</z:chebi>, <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and immunosuppressive drugs in severe cases </plain></SENT>
<SENT sid="3" pm="."><plain>Anti-TNF-α therapy may be useful in refractory severe BD, particularly for ocular, central <z:mp ids='MP_0008912'>nervous</z:mp> system, gastrointestinal and refractory mucocutaneous lesions </plain></SENT>
<SENT sid="4" pm="."><plain>During a 2-year period, 280 patients suffering from <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> received anti-TNF-α agents at the infusion center of our University Hospital </plain></SENT>
<SENT sid="5" pm="."><plain>Two patients (0.7%) presented BD; one of them had <z:hpo ids='HP_0002608'>celiac disease</z:hpo> as well, with recalcitrant mucocutaneous lesions that were not responsive to immunosuppressive drugs </plain></SENT>
<SENT sid="6" pm="."><plain>We reported those patients who were successfully treated with infliximab and adalimumab, despite their late response </plain></SENT>
</text></document>